1). check details To date 15 vaccines are recommended to be included in the national immunization programmes in the Americas2. For example, influenza vaccines had greatest uptake in this region of the world with 40 countries adopting seasonal vaccination, with majority for elderly, health workers and persons with chronic diseases, and approximately half of the countries offering

vaccination to pregnant women and children. The PAHO Revolving Fund represents for manufacturers a “single window” to access 40 countries, a vaccine market with sustainable demand, prompt payment, post marketing surveillance, among other features. Also 60 days credit line to countries supports promptly placement of purchase orders. Presently there are needs for yellow fever supply, varicella and DTaP. Also the Region represents an opportunity for increasing competition for seasonal influenza, PCV, Rotavirus, and HPV vaccines. M. Malhame presented the GAVI Alliance Vaccine Investment Strategy update, which is the mechanism to make decisions

for support to introduction of vaccines in the poor countries financed by GAVI. In 2008 the GAVI board asked for a comprehensive process, instead of case-studies, as in the previous BGJ398 solubility dmso years to define the funding portfolio. Based on analytical data, including demand forecast, Carnitine dehydrogenase and technical and country consultations, surveys and interviews with stakeholders along

the last 12 months, 15 vaccines were reviewed according to demand, cost, impact and other features. Five vaccines were prioritized: malaria and maternal influenza based on to public health impact, cholera and yellow fever based on epidemic potential, and rabies based on cost-effectiveness (cost per death averted). The prioritized vaccines were discussed at the board meeting on November 21st, and two vaccines were selected: malaria, cholera stockpile and additional yellow fever campaigns. GAVI will reevaluate the vaccine landscape in 2018. The speakers, moderated by K. Bush and M. Datla, discussed the challenges of global vaccines’ procurement. K. Bush acknowledged the DCVM group for commitment and investments in vaccines manufacturing, and mentioned that the BMGF works through partnerships: there is no purchase, no storage, but help through not-for-profit partners. He explained that the life sciences group at the Foundation focuses on industry partnerships for a deeper and broader engagement and understand the industry capabilities and sustainability of goals. The group has dedicated resources for working with multinationals, biotech, and DCVMs that have different operating models and expectations. Another group working with vaccine policy groups supports the interface between supply and demand.